IN2012DN00572A - - Google Patents

Download PDF

Info

Publication number
IN2012DN00572A
IN2012DN00572A IN572DEN2012A IN2012DN00572A IN 2012DN00572 A IN2012DN00572 A IN 2012DN00572A IN 572DEN2012 A IN572DEN2012 A IN 572DEN2012A IN 2012DN00572 A IN2012DN00572 A IN 2012DN00572A
Authority
IN
India
Prior art keywords
compositions
treating
methods
provides
present
Prior art date
Application number
Inventor
Kristen Johnson
Lori Jennings
Peter Schultz
Original Assignee
Scripps Research Inst
Irm Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43450138&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00572(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Scripps Research Inst, Irm Llc filed Critical Scripps Research Inst
Publication of IN2012DN00572A publication Critical patent/IN2012DN00572A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1891—Angiogenesic factors; Angiogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/515—Angiogenesic factors; Angiogenin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/23—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a GST-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/24—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a MBP (maltose binding protein)-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Vascular Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Microbiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The present invention provides for methods and compositions for treating or preventing arthritis and joint injury.
IN572DEN2012 2009-07-14 2010-07-13 IN2012DN00572A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22529309P 2009-07-14 2009-07-14
PCT/US2010/041850 WO2011008773A2 (en) 2009-07-14 2010-07-13 Mesenchymal stem cell differentiation

Publications (1)

Publication Number Publication Date
IN2012DN00572A true IN2012DN00572A (en) 2015-06-12

Family

ID=43450138

Family Applications (1)

Application Number Title Priority Date Filing Date
IN572DEN2012 IN2012DN00572A (en) 2009-07-14 2010-07-13

Country Status (31)

Country Link
US (4) US9139633B2 (en)
EP (1) EP2453921B1 (en)
JP (1) JP5602850B2 (en)
KR (3) KR101590834B1 (en)
CN (2) CN105601728B (en)
AU (1) AU2010273570B2 (en)
BR (1) BR112012000914B8 (en)
CA (1) CA2767826C (en)
CL (1) CL2012000091A1 (en)
CO (1) CO6491059A2 (en)
CR (1) CR20120024A (en)
CU (1) CU24042B1 (en)
EA (1) EA023073B1 (en)
EC (1) ECSP12011604A (en)
ES (1) ES2541217T3 (en)
GT (1) GT201200011A (en)
HK (1) HK1164169A1 (en)
IL (2) IL217383A (en)
IN (1) IN2012DN00572A (en)
MA (1) MA33423B1 (en)
MX (1) MX2012000707A (en)
MY (1) MY160951A (en)
NZ (1) NZ597306A (en)
PE (2) PE20160507A1 (en)
PL (1) PL2453921T3 (en)
PT (1) PT2453921E (en)
SG (1) SG177318A1 (en)
TN (1) TN2011000655A1 (en)
UA (1) UA104031C2 (en)
WO (1) WO2011008773A2 (en)
ZA (1) ZA201200078B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA33423B1 (en) * 2009-07-14 2012-07-03 Scripps Research Inst Differentiation of mesenchymal stem cells
JO3412B1 (en) 2011-06-17 2019-10-20 Regeneron Pharma Anti-angptl3 antibodies and uses thereof
KR101615662B1 (en) 2011-11-08 2016-04-26 한국전자통신연구원 Method and apparratus of video decoding
US9790264B2 (en) 2012-06-25 2017-10-17 The Brigham And Women's Hospital, Inc. Compounds and methods for modulating pharmacokinetics
EP3369747A1 (en) * 2012-06-25 2018-09-05 The Brigham and Women's Hospital, Inc. Targeted theratpeutics
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (en) * 2013-03-08 2020-07-05 Novartis Ag Peptides and compositions for treatment of joint damage
WO2014151953A1 (en) 2013-03-15 2014-09-25 The California Institute For Biomedical Research Compounds and methods for inducing chondrogenesis
JP6479051B2 (en) 2014-05-13 2019-03-06 ノバルティス アーゲー Compounds and compositions for inducing cartilage formation
CN104840486A (en) * 2015-04-30 2015-08-19 北京益诺勤生物技术有限公司 Composition, application thereof and preparation
AU2017357785A1 (en) * 2016-11-14 2019-04-11 Novartis Ag Methods and compositions for treatment of cartilage damage and arthritis
JOP20190282A1 (en) 2017-06-09 2019-12-05 Novartis Ag Compounds and compositions for inducing chondrogenesis
AR116566A1 (en) 2018-10-03 2021-05-19 Novartis Ag SUSTAINED ADMINISTRATION OF ANGIOPOYETIN-SIMILAR POLIPEPTIDES 3
WO2020115684A1 (en) 2018-12-06 2020-06-11 Novartis Ag 6-hydroxy-8-oxatricyclo[3.2.1.02,4]octane-2-carboxamide derivatives for inducing chondrogenesis for treating joint damage
JP7471291B2 (en) 2018-12-06 2024-04-19 ノバルティス アーゲー 5-hydroxy-7-oxabicyclo[2.2.1]heptane-2-carboxamide derivatives for inducing cartilage formation to treat joint injuries - Patents.com
CN109432128A (en) * 2018-12-07 2019-03-08 卡替（上海）生物技术股份有限公司 Application of the dental pulp mescenchymal stem cell in curing psoriasis
KR102246582B1 (en) * 2019-04-03 2021-04-30 이화여자대학교 산학협력단 Method for inducing differentiation stem cells into chondrocytes using oligopeptides

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5462990A (en) * 1990-10-15 1995-10-31 Board Of Regents, The University Of Texas System Multifunctional organic polymers
US5972338A (en) * 1997-09-19 1999-10-26 Genentech, Inc. Tie ligands homologues
WO1999055869A1 (en) 1998-04-27 1999-11-04 Zymogenetics, Inc. Novel polypeptide growth factors and materials and methods for making them
JP2002533058A (en) 1998-05-12 2002-10-08 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド 97 human secreted proteins
AU4643699A (en) 1998-06-24 2000-01-10 Compugen Ltd. Angiopoietin-like growth factor sequences
CA2361849A1 (en) 1999-03-08 2000-09-14 Genentech, Inc. Promotion or inhibition of angiogenesis and cardiovascularization
AU4011300A (en) * 1999-07-20 2001-02-05 Genentech Inc. Compositions and methods for the treatment of immune related diseases
US20030013649A1 (en) * 2000-01-31 2003-01-16 Rosen Craig A. Nucleic acids, proteins, and antibodies
US20030144498A1 (en) * 2000-10-16 2003-07-31 Audrey Goddard TIE ligand homologues
EP1927659B1 (en) * 2000-10-16 2010-01-27 Genetech, Inc. Wisp polypeptides and therapeutical applications thereof
US20030027751A1 (en) * 2001-04-10 2003-02-06 Genvec, Inc. VEGF fusion proteins
US20030194798A1 (en) * 2001-05-24 2003-10-16 Surber Mark W. Minicell compositions and methods
CN1615440A (en) * 2001-11-16 2005-05-11 杰南技术公司 Composition comprising and method of using angiopoietin-like protein 3 ANGPTL3
NZ538624A (en) * 2002-09-09 2007-01-26 Nektar Therapeutics Al Corp Water-soluble polymer alkanals
WO2004081174A2 (en) * 2003-03-10 2004-09-23 Japan Science And Technology Agency Marker for detecting mesenchymal stem cell and method of distinguishing mesenchymal stem cell using the marker
JP3979372B2 (en) 2003-09-26 2007-09-19 ブラザー工業株式会社 Image processing apparatus, image processing method, and image processing program
ATE551066T1 (en) * 2004-06-21 2012-04-15 Cleveland Clinic Foundation CCR LIGANDS FOR STEM CELL HOMING
AU2006223579A1 (en) 2005-03-11 2006-09-21 Genentech, Inc. Gene disruptions, compositions and methods relating thereto
US7807464B2 (en) 2005-05-24 2010-10-05 Whitehead Institute For Biomedical Research Methods for expansion and analysis of cultured hematopoietic stem cells
US7601501B2 (en) * 2006-08-11 2009-10-13 The Scripps Research Institute Controlling osteogenesis by inhibition of osteogenic suppressors
WO2008137641A2 (en) * 2007-05-04 2008-11-13 Whitehead Institute For Biomedical Research Ex vivo expansion of human hematopoietic stem cells
US20090104210A1 (en) 2007-10-17 2009-04-23 Tota Michael R Peptide compounds for treating obesity and insulin resistance
MA33423B1 (en) * 2009-07-14 2012-07-03 Scripps Research Inst Differentiation of mesenchymal stem cells
US9301971B2 (en) 2013-03-08 2016-04-05 Novartis Ag Peptides and compositions for treatment of joint damage
JO3564B1 (en) 2013-03-08 2020-07-05 Novartis Ag Peptides and compositions for treatment of joint damage

Also Published As

Publication number Publication date
CN105601728A (en) 2016-05-25
EP2453921A2 (en) 2012-05-23
EA201200118A1 (en) 2012-09-28
CR20120024A (en) 2012-06-11
CO6491059A2 (en) 2012-07-31
ES2541217T3 (en) 2015-07-16
TN2011000655A1 (en) 2013-05-24
US20160213748A1 (en) 2016-07-28
CA2767826C (en) 2015-11-24
KR101590834B1 (en) 2016-02-12
CU20120007A7 (en) 2013-02-26
US20200108122A1 (en) 2020-04-09
KR20160015403A (en) 2016-02-12
HK1164169A1 (en) 2012-09-21
PL2453921T3 (en) 2015-11-30
BR112012000914B1 (en) 2021-04-06
KR20180000337A (en) 2018-01-02
BR112012000914B8 (en) 2021-05-25
KR20120029472A (en) 2012-03-26
CN105601728B (en) 2020-01-10
ECSP12011604A (en) 2012-06-29
BR112012000914A8 (en) 2017-12-19
JP5602850B2 (en) 2014-10-08
MA33423B1 (en) 2012-07-03
EP2453921A4 (en) 2012-12-19
PT2453921E (en) 2015-09-25
UA104031C2 (en) 2013-12-25
BR112012000914A2 (en) 2017-08-08
CL2012000091A1 (en) 2012-10-26
AU2010273570A1 (en) 2012-02-02
WO2011008773A3 (en) 2011-08-25
US10555990B2 (en) 2020-02-11
PE20120570A1 (en) 2012-05-19
AU2010273570B2 (en) 2014-07-03
MX2012000707A (en) 2012-03-21
US9139633B2 (en) 2015-09-22
US20190000922A1 (en) 2019-01-03
JP2012533549A (en) 2012-12-27
IL217383A0 (en) 2012-02-29
WO2011008773A2 (en) 2011-01-20
US11241482B2 (en) 2022-02-08
CN102625830B (en) 2016-03-02
CN102625830A (en) 2012-08-01
MY160951A (en) 2017-03-31
EP2453921B1 (en) 2015-05-27
US20120177644A1 (en) 2012-07-12
NZ597306A (en) 2014-03-28
IL247310B (en) 2018-04-30
EA023073B1 (en) 2016-04-29
IL217383A (en) 2016-08-31
ZA201200078B (en) 2013-01-30
US10064918B2 (en) 2018-09-04
CA2767826A1 (en) 2011-01-20
GT201200011A (en) 2013-12-10
SG177318A1 (en) 2012-03-29
PE20160507A1 (en) 2016-05-20
CU24042B1 (en) 2014-11-27

Similar Documents

Publication Publication Date Title
IN2012DN00572A (en)
MX2021000710A (en) Compositions comprising bacterial strains.
MX2009008222A (en) Activin-actriia antagonists and uses for treating or preventing breast cancer.
EP2569330A4 (en) Chlorotoxin variants, conjugates, and methods for their use
MX338884B (en) Compositions and methods comprising protease variants.
MY151551A (en) Oxadiazole- and oxazole-substituted benzimidazole- and indole-derivatives as dgat1 inhibitors
IN2012DN03883A (en)
MY173616A (en) Compositions and methods for lowering triglycerides
WO2008124660A3 (en) Methods and compositions for the treatment of cancer
MX2014010455A (en) Methods and compositions for treating huntington's disease.
UA104459C2 (en) Anti-fgfr3 antibodies and methods using same
MX2013005065A (en) Pesticidal compositions and processes related thereto.
MX2009009761A (en) Compositions and kits for treating influenza.
MX2014011134A (en) Carbamate compounds and of making and using same.
MX344786B (en) Compositions and methods for treating gaucher disease.
GB2530921A (en) C1-INH compositions and methods for the prevention and treatment of disorders associated with C1 esterase inhibitor deficency
BRPI1007929A2 (en) "methods and compositions for treating neovascularization".
MX2009011346A (en) Tapentadol for treating pain from arthritis.
IN2012DN02624A (en)
WO2011009890A3 (en) Use of azabicycloalkyl derivatives or pyrrolidine - 2 - one derivatives for the treatment or prevention of ataxia
EP4023243A3 (en) Compositions and methods for treating celiac sprue disease
WO2012017321A3 (en) Treatment for dyslipidemia
WO2010037095A3 (en) Agents and methods for the treatment of cancer
MX2010002950A (en) Methods and compositions for detection of ehrlichia chaffeensis (vlpt).
MX2022011897A (en) Methods and compositions for treatment of cartilage damage and arthritis.